PatrĂ­cia Silva, PhD, director of science content —

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

Sunovion and Novartis Enter Agreement to Market 3 COPD Treatments in US

Sunovion Pharmaceuticals and Novartis have entered a commercialization agreement for three drugs approved by the U.S. Food and Drug Administration (FDA) indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder (27.5 mcg/15.6…

Outstanding Investigator Award Goes to Professor for Lung Disease Antioxidant Studies

The National Heart, Lung and Blood Institute (NHLBI) has named the recipient of its inaugural Outstanding Investigator Award: Yvonne Janssen-Heininger, PhD, professor of pathology and laboratory medicine at the Larner College of Medicine at the University of Vermont, to conduct studies on antioxidant therapies for lung diseases, including chronic obstructive pulmonary…

InMed Announces Progress on COPD Treatment Using Cannabinoids

InMed Pharmaceuticals announced that its research and development program using cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD) has made new progress. The company initiated its COPD program in June 2015, leveraging its bioinformatics analysis tool to identify the targets and potential active compounds that could be used…

GOLD Treatment Recommendations Now Include Endobronchial Valves to Manage COPD

Newly updated chronic obstructive pulmonary disease (COPD) management recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) now include the reduction in bronchoscopic lung volume through the use of endobronchial valves as a treatment option for patients suffering with advanced emphysema and absence of collateral ventilation. The new recommendations are…

GSK Submits FDA New Drug Application for COPD Triple Combination Therapy

GlaxoSmithKline (GSK), together with Innoviva, recently announced GSK submitted a New Drug Application (NDA) with the U.S. FDA for the triple combination therapy FF/UMEC/VI (fluticasone furoate/umeclidinium/vilanterol) to treat chronic obstructive pulmonary disease (COPD). GSK announced earlier this year that it was planning to advance the timing of the filing with…